Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib

Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations

(2015) Anwar R. Padhani et al.   NEOPLASIA

The IGR-CaP1 Xenograft Model Recapitulates Mixed Osteolytic/Blastic Bone Lesions Observed in Metastatic Prostate Cancer

(2015) Nader Al Nakouzi et al.   NEOPLASIA

Multimodality Imaging of Tumor and Bone Response in a Mouse Model of Bony Metastasis

(2014) Benjamin A. Hoff et al.   Translational Oncology

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

(2012) David C. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Bony metastases: assessing response to therapy with whole-body diffusion MRI

(2012) A.R. Padhani et al.   CANCER IMAGING

Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients

(2011) R. Mehra et al.   CLINICAL CANCER RESEARCH

Assessing response in bone metastases in prostate cancer with diffusion weighted MRI

(2011) C. Messiou et al.   EUROPEAN RADIOLOGY

Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility

(2011) C. Messiou et al.   EUROPEAN RADIOLOGY

Emerging Therapies to Prevent Skeletal Morbidity in Men With Prostate Cancer

(2011) Philip J. Saylor et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

The Bone Scan

(2011) Arnold I. Brenner et al.   SEMINARS IN NUCLEAR MEDICINE

Guidelines for the welfare and use of animals in cancer research

(2010) P Workman et al.   BRITISH JOURNAL OF CANCER

New molecular targets in bone metastases

(2010) D. Santini et al.   CANCER TREATMENT REVIEWS

PSA as an intermediate end point in clinical trials

(2009) Gerhardt Attard et al.   Nature Reviews Urology

Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study

(2008) D. R. Berthold et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER